Home RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study
 

Keywords :   


RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study

2014-04-30 11:16:46| Biotech - Topix.net

RXI-109 is an sd-rxRNA compound that targets connective tissue growth factor and is being developed for the treatment of abnormal dermal scars, such as hypertrophic scars and keloids, in conjunction with scar or keloid revision surgery.

Tags: study phase announces initiation

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
25.111/18CTS-V
25.11
25.111
25.11ARS 10+ EHERO 3
25.11 16MGL HG
25.11
25.11GREENMAX 4470 22600Ace4
25.11
More »